SREBP-1C is one of the major transcriptional factors involved in de novo lipid synthesis, which affects NAFLD through the nuclear transcription factor farnesoid X receptor (FXR) [41]. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.